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Cortical lesions constitute an important part of multiple sclerosis pathology. Although inflammation appears to play a role
in their formation, the mechanisms leading to demyelination and neurodegeneration are poorly understood. We aimed to
identify some of these mechanisms by combining gene expression studies with neuropathological analysis. In our study, we
showed that the combination of inflammation, plaque-like primary demyelination and neurodegeneration in the cortex is specific
for multiple sclerosis and is not seen in other chronic inflammatory diseases mediated by CD8-positive T cells (Rasmussen’s
encephalitis), B cells (B cell lymphoma) or complex chronic inflammation (tuberculous meningitis, luetic meningitis or chronic
purulent meningitis). In addition, we performed genome-wide microarray analysis comparing micro-dissected active cortical
multiple sclerosis lesions with those of tuberculous meningitis (inflammatory control), Alzheimer’s disease (neurodegenerative
control) and with cortices of age-matched controls. More than 80% of the identified multiple sclerosis-specific genes were
related to T cell-mediated inflammation, microglia activation, oxidative injury, DNA damage and repair, remyelination and
regenerative processes. Finally, we confirmed by immunohistochemistry that oxidative damage in cortical multiple sclerosis
lesions is associated with oligodendrocyte and neuronal injury, the latter also affecting axons and dendrites. Our study provides
new insights into the complex mechanisms of neurodegeneration and regeneration in the cortex of patients with multiple
sclerosis.
Keywords: multiple sclerosis; cortex; gene expression; demyelination; neurodegeneration
Abbreviation: PLP = proteolipid protein; TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling
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Introduction
Multiple sclerosis is traditionally seen as a disease that affects the
white matter giving rise to focal inflammatory demyelinating le-
sions (Lassmann et al., 2007). Recent studies on the pathology of
multiple sclerosis, however, challenged this concept by providing
evidence for extensive grey matter lesions in the cerebral (Peterson
et al., 2001; Bo et al., 2003; Kutzelnigg et al., 2005) and cere-
bellar cortex (Kutzelnigg et al., 2007) and in the hippocampus
(Geurts et al., 2007). Despite the primary demyelinating nature
of cortical lesions, profound degeneration also affects cortical neu-
rons, axons and synapses (Peterson et al., 2001; Wegner et al.,
2006; Dutta and Trapp, 2011).
Cortical lesions arising during early (Lucchinetti et al., 2011) and
late (Kutzelnigg et al., 2005; Howell et al., 2011) disease stages
are associated with inflammation. In lesions developing in the pro-
gressive stage, the degree of meningeal inflammation correlates
with the extent of active demyelination and neurodegeneration
(Howell et al., 2011; Choi et al., 2012). Thus, inflammation may
drive cortical lesions, but it remains unresolved, whether cortical
primary demyelination is a multiple sclerosis-specific event, which
types of inflammatory cells are involved and which molecular
mechanisms evoke tissue injury. In this study, we compared cor-
tical pathology in multiple sclerosis with that seen in a large spec-
trum of other inflammatory and neurodegenerative brain diseases
and found that the combination of inflammation, plaque-like pri-
mary demyelination and neurodegeneration is specific for multiple
sclerosis. The second part of the study focused on global gene
expression studies analysing potential molecular pathways of
tissue injury in active cortical multiple sclerosis lesions. The latter
were defined by the presence of macrophages containing degrad-
ation products reactive for myelin or neuronal antigens. Since the
data suggested oxidative injury, DNA damage, and apoptosis as
potential mechanisms of tissue degeneration, we analysed the ex-
pression of proteins involved in oxidative burst as well as the pres-
ence of oxidized lipids and DNA fragmentation in a broad sample
of cortical multiple sclerosis lesions in comparison with the normal
and diseased controls using immunohistochemistry and terminal
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
staining.
Materials and methods
Sample characterization
Archival formaldehyde-fixed and paraffin-embedded (FFPE) autopsy
material collected in the archives of the Centre for Brain Research
and the Institute of Neurology were used (Table 1). The study was
approved by the Ethical Committee of the Medical University of
Vienna (EK. No. 535/2004 and 087/01/2012). It included 21 cases
of multiple sclerosis comprising acute multiple sclerosis (n = 6), relap-
sing-remitting multiple sclerosis (n = 1), secondary progressive multiple
sclerosis (n = 7) and primary progressive multiple sclerosis (n = 7). As
controls, cases of chronic tuberculous meningitis (n = 4), luetic menin-
gitis (n = 1), chronic purulent meningitis (n = 1), Rasmussen’s enceph-
alitis (n = 5), B cell lymphomas affecting meninges and cortex
(including one EBV + lymphoma; n = 4), Alzheimer’s disease (n = 11)
and age-matched controls without any detectable brain disease (con-
trol subjects; n = 17) were included. For basic neuropathology of each
case, multiple tissue blocks from all brain regions were stained with
haematoxylin/eosin, Luxol Fast blue myelin stain and Bielschowsky
silver impregnation. The selection of tissue blocks taken for microarray
and neuropathological analysis depended on the clinical diagnosis of
each patient (Table 1). For microarray analysis we selected frontal
association cortex for multiple sclerosis and controls, frontobasal
(TB1 and TB2) and temporobasal (TB3) cortex for tuberculous menin-
gitis and temporal cortex for Alzheimer’s disease. For neuropatho-
logical studies the blocks (between three and eight) from patients
with Alzheimer’s disease or tuberculous meningitis included cortical
areas (frontal, temporal, parietal and occipital), while in case of B
cell lymphoma between one and three blocks were chosen, which
contained infiltration of neoplastic B cells in meninges or cortex
(frontal and parietal). Tissue samples from patients with Rasmussen’s
encephalitis derived from temporal cortico/subcortical neurosurgical
resections and were, thus, restricted to one block per case. For control
cases, basic neuropathology was performed on eight to 15 tissue
blocks from all brain regions to exclude confounding pathology.
From those three to six blocks comprising frontal, parietal, and tem-
poral cortex were selected for further analysis. In multiple sclerosis
cases, cortical lesions were either identified by analysis of multiple
tissue blocks (n = 10 cases) or were specifically trimmed from hemi-
spheric or double hemispheric sections (n = 11 cases). The architecture
of active cortical lesions was complex. In general, they contained a
fully demyelinated area, which was surrounded by an area of variable
size with reduced myelin density and profound microglia activation,
located between the demyelinated lesion and the normal appearing
grey matter. However, microglia activation alone was not sufficient for
the identification of an active lesion, since a rim of activated (iron
containing) microglia can be seen in multiple sclerosis lesions, which
do not expand in the subsequent years (Bian et al., 2012). Thus, we
used the presence of degradation products in macrophages reactive
for myelin or neuronal antigens, such as neurofilament, as an add-
itional marker for active cortical lesions (Fig. 1 and Supplementary
Fig. 1). For the investigation of molecular mechanisms of tissue
injury by microarray analysis, we selected subpial cortical lesions with
a zone of perilesional activity as defined above.
Immunohistochemistry
Consecutive 5 -mm thick serial sections were cut, routinely deparaffi-
nized and endogenous peroxidase was blocked with H2O2/methanol.
Non-specific antibody binding was blocked by incubating the section
in 10% foetal calf serum. Antigen retrieval procedures and primary
antibodies used for immunohistochemistry are listed in Table 2.
Primary antibodies were applied overnight at 4C. For immunohisto-
chemical controls, either primary antibodies were omitted or unrelated
sera or monoclonal antibodies of the same immunoglobulin class were
used. Antibody binding was routinely visualized using 3,3’-diamino-
benzidine, which was occasionally enhanced by biotinylated tyramine
amplification (King et al., 1997). Alternatively, Fast blue B salt or 3-
amino-9-ethylcarbazole were used for signal development. Before
mounting of sections, cell nuclei were counterstained with
haematoxylin.
Confocal fluorescence immunohistochemistry was performed on
paraffin sections as described for light microscopy with some modifi-
cations. For fluorescent double labelling with primary antibodies from
different species (mouse-anti-E06 and goat-anti-carbonic anhydrase II,
rabbit-anti-GFAP, rabbit-anti-neurofilament or rabbit-anti-calbindin,
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respectively), antibodies were applied simultaneously at 4C overnight.
After washing, secondary antibodies (biotin-conjugated donkey-anti-
rabbit, 1:200; Cy3-conjugated donkey-anti-goat, 1:200; Cy2-conju-
gated donkey-anti-mouse, 1:200; all antibodies from Jackson
ImmunoResearch) were applied simultaneously for 1 h at room tem-
perature. This procedure was followed by application of streptavidin-
Cy5 (Jackson ImmunoResearch; 1:75) for 1 h at room temperature.
Finally, fluorescent preparations were embedded and examined using
a confocal laser scan microscope (Leica SP5) equipped with lasers for
488, 543 and 633 nm excitation. Scanning for Cy2 (488 nm), Cy3
(543 nm) and Cy5 (633 nm) was done sequentially to rule out fluor-
escence bleed through.
TUNEL staining for DNA damage
TUNEL staining was performed essentially as described previously
(Gold et al., 1993) and has already successfully been applied previ-
ously for analysis of DNA fragmentation in Alzheimer’s disease and
controls (Lassmann et al., 1995). In the present study we used the
In Situ Cell Death Detection Kit (Roche).
Quantification of
immunohistochemistry and TUNEL
staining
CD3-positive T cells, CD68-positive macrophages, TPPP/p25-positive
oligodendrocytes, neurofilament-reactive dystrophic axons, neuronal
cell bodies, E06-positive neurons and TUNEL-positive cells were
counted. In case of neuronal quantification, only neurons containing
a nucleus with a prominent nucleolus were included. Counting of
neurons, oligodendrocytes, dystrophic axons and TUNEL-positive
cells was performed in cortical layers III to V. Quantitative analysis
was done using a morphometric grid within the ocular lens counting
10 microscopic fields of 0.0576 mm2 per region of interest (normal
appearing grey matter and lesion). Presented values were calculated
as counts/mm2 tissue area. Quantitative enumeration of T cells and
macrophages was done in the entire cortex, including the meninges,
positioning the grid areas in parallel rows, spanning the entire cortical
ribbon. The percentage of neurons with intense cytoplasmic reactivity
for oxidized phospholipids (E06 reactivity) is shown in relation to the
Table 1 Clinical demographics
Case
ID
Details Age Sex Disease
duration
Progressive
phase
duration
Total
number
of tissue
blocks
Block
types
MS1* SPMS 42 F 216 months 168 months 6 C
MS2* SPMS 41 M 137 months n.a. 34 A, C
MS3* SPMS 46 F 444 months 228 months 21 A, C
MS4 AMS 34 F 4 months 0 1 B
MS5 AMS 35 M 1.5 months 0 11 A, C
MS6 AMS 45 M 0.2 months 0 3 B
MS7 AMS 45 M 0.6 months 0 3 B, C
MS8 AMS 52 M 1.5 months 0 3 C
MS9 AMS 78 M 2 months 0 14 C
MS10 RRMS 57 F 156 months 0 13 B, C
MS11 SPMS 66 F 96 months n.a. 39 C
MS12 SPMS 34 M 120 months n.a. 16 C
MS13 SPMS 53 F 241 months 104 months 23 A, C
MS14 SPMS 56 M 372 months 126 months 46 A, C
MS15 PPMS 55 F 60 months 60 months 10 A, C
MS16 PPMS 54 F 72 months 72 months 12 C
MS17 PPMS 67 M 87 months 87 months 41 A, C
MS18 PPMS 77 F 168 months 168 months 11 C
MS19 PPMS 53 M 168 months 168 months 16 C
MS20 PPMS 34 M 204 months 204 months 7 C
MS21 PPMS 71 F 264 months 264 months 9 C
TB1* 67 F 1 month 15 C
TB2* 48 M n.a. 6 C
TB3* 24 F 2 weeks 4 C
TB4 19 M 1 month 8 C
LU1 58 F n.a. 2 C
ME1 62 M 8 days 1 C
BLY1 59 F n.a. 3 C
BLY2 63 F 3 weeks 10 C
BLY3 71 M 11 months 11 C
BLY4 EBV + 47 M 1.5 months 22 C
RAE1 3.9 F 17 months 1 D
RAE2 15 F 7.5 months 1 D
RAE3 22 M 7.1 months 1 D
RAE4 24 M 58 months 1 D
RAE5 28 F 27 months 1 D
AD1* Braak VI 89 F 36 months 8 C
AD2* Braak VI 82 F 90 months 5 C
AD3* Braak VI 60 F 72 months 24 C
AD4 Braak III 66 F n.a. 22 C
AD5 Braak V 70 F 96 months 8 C
AD6 Braak IV 79 F 60 months 10 C
AD7 Braak IV 81 F 36 months 23 C
AD8 Braak V 86 F 60 months 7 C
AD9 Braak VI 86 F n.a. 8 C
AD10 Braak VI 86 F n.a. 10 C
AD11 Braak IV 92 F n.a. 7 C
CO1* 45 F 0 5 C
CO2* 46 M 0 3 C
CO3* 65 M 0 4 C
CO4 30 F 0 3 C
CO5 36 F 0 3 C
CO6 39 F 0 3 C
CO7 37 M 0 4 C
CO8 42 F 0 3 C
CO9 47 F 0 3 C
CO10 70 M 0 3 C
CO11 71 F 0 3 C
CO12 71 F 0 3 C
CO13 72 M 0 3 C
(continued)
Table 1 Continued
Case
ID
Details Age Sex Disease
duration
Progressive
phase
duration
Total
number
of tissue
blocks
Block
types
CO14 83 M 0 6 C
CO15 84 F 0 3 C
CO16 88 F 0 3 C
CO17 97 F 0 3 C
MS = multiple sclerosis; AMS = acute MS; RRMS = relapsing remitting MS;
PPMS = primary progressive multiple sclerosis; SPMS = secondary
progressive multiple sclerosis; TB = tuberculous meningitis; LU = luetic
meningitis; ME = chronic purulent meningitis; BLY = B-cell lymphoma;
RAE = Rasmussen’s encephalitis; AD = Alzheimer’s disease; Braak = Braak
stages of Alzheimer’s disease; CO = control without neurological disease or
brain lesions; f = female; m = male; n.a. = data not available; * = case
included in microarray study printed in bold; Block types: A = double
hemispheric blocks; B = single hemispheric blocks; C = conventional blocks
(2  3 cm).
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Figure 1 Plaque-like primary demyelination is specific for multiple sclerosis. (A–E) Highly inflammatory, active cortical lesion from Case
MS1. Extensive subpial demyelination [A; immunohistochemistry (IHC) for PLP] is associated with inflammatory infiltrates in the meninges
and the perivascular space. Profound activation of microglia is visible in the lesion and in the adjacent periplaque grey matter (B; IHC for
HLA-D). CD3-positive T lymphocytes are present in the perivascular inflammatory cuffs and diffusely dispersed throughout the lesion
(C; IHC for CD3). Phagocytic macrophages are also present in the perivascular inflammatory cuffs and in the parenchyma (D; IHC for
CD68). They in part contain myelin degradation products reactive for PLP (E; IHC for PLP). (F-I) Chronic, active cortical lesion from
1802 | Brain 2013: 136; 1799–1815 M. T. Fischer et al.
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total number of counted cortical neurons. To examine the extent of
demyelination, proteolipid protein (PLP)-stained slides were scanned
and the extent of demyelination was calculated as demyelinated
area in relation to total cortex area.
RNA extraction and microarrays
For gene expression studies, three active multiple sclerosis lesions (the
fulminate active lesion of Case MS1 and two chronic active lesions
from Cases MS2 and MS3), three cortex samples from patients with
tuberculous meningitis, three Alzheimer’s disease cases, and three con-
trols without brain pathology were selected (Table 1).
As archival formaldehyde-fixed and paraffin-embedded autopsy ma-
terial with unknown time spans and storage conditions between sam-
pling and fixation was used, RNA preservation of more than 150
multiple sclerosis tissue blocks and 40 tissue blocks containing control
material (Alzheimer’s disease, tuberculous meningitis, control subjects),
was assessed by in situ hybridization for PLP as described (Breitschopf
et al., 1992). Tissue blocks with strong and specific in situ hybridiza-
tion signals in oligodendrocytes after short development time (510 h)
were selected for further studies. Ten to 20 6–10 -mm thick sections
were cut under RNase-free conditions. Cortical tissue blocks for micro-
array analysis were selected according to the presence of lesions typ-
ical for the different disease entities. Cortical areas including all cortical
layers from Alzheimer’s disease, tuberculous meningitis and control
subjects were micro-dissected. In tuberculous meningitis cases, these
cortical areas were further restricted to sites with profound meningeal
and parenchymal inflammation. For multiple sclerosis cases, we micro-
dissected cortical areas with subpial demyelination of at least the outer
four cortical layers. These lesions contained a broad zone around the
plaque with profound microglia activation and the presence of macro-
phages with degradation products reactive for myelin or neuronal anti-
gens. Thus, for messenger RNA analysis, these multiple sclerosis blocks
also contained all cortical layers and, dependent on the degree of
activity, a zone of variable size with signs of active tissue injury.
Isolation, amplification, and quality assessment of messenger RNA
were done as extensively described before (Fischer et al., 2012).
Briefly, total RNA was isolated using the High Pure FFPE RNA Micro
Kit (Roche) according to the manufacturer’s instructions. The concen-
tration of isolated total RNA was too low for any RNA integrity
measurements. Instead, messenger RNA was amplified using poly(T)
primers and the Arcturus Paradise FFPE Amplification Kit (Applied
Biosystems, Life Technology). After the first round of in vitro transcrip-
tion, the quality of the samples was tested. Owing to RNA fragmen-
tation and cross-linking during formaldehyde fixation, it is almost
impossible to isolate full length RNA from formaldehyde-fixed and
paraffin-embedded tissue. Therefore, routine endpoint PCR for the
housekeeping gene actin, beta (ACTB) was performed to verify that
RNA fragments were sufficiently long to use them as probes for micro-
arrays. Primers were designed in such a way that the forward primer
binds 472 bases upstream of the poly(A) tail. Endpoint PCR was run
with the following settings: forward: 5’-TTGACTCAGGATTTAAAA
ACTGG-3’, reverse: 5’-AGGGACTTCCTGTAACAACGC-3’; 10 min
denaturation; followed by 40 cycles of denaturation (30 s, 95C), an-
nealing (30 s, 55C), and extension (30 s, 72C). Only when a suffi-
cient amount of PCR product was found, the samples qualified for a
second round of in vitro amplification. The resulting antisense RNA
was sent out for hybridization to Agilent-014850 Whole-Human
Genome Microarrays 4x44K (G4112F). RNA labelling, microarray hy-
bridization and scanning, as well as quantile normalization of raw data
were carried out externally (Source BioScience imaGenes GmbH).
For data analysis, two different approaches were used. On the one
hand, all genes significantly changed (P5 0.01; Student’s t-test) in
cases with multiple sclerosis (Cases MS1–3) in comparison with other
cases (Alzheimer’s disease, tuberculous meningitis and control subjects)
were evaluated. On the other hand, to have the ability to assess the
inflammatory component of the fulminate lesion of Case MS1, all
massively up- or down regulated genes (log2 fold-changes 44 or
54.5, respectively) in Case MS1 in comparison with all other
cases (other multiple sclerosis, Alzheimer’s disease, tuberculous men-
ingitis and control subjects) were examined. As significance testing was
not possible for this analysis approach, restrictive cut-offs were used
instead. They were based on the observation that above and below a
log2 fold-change of 4 and 4.5, respectively, the detected differences
were granted to be exclusively present in Case MS1, whereas the gene
expression values in all other cases (tuberculous meningitis, Alzheim-
er’s disease and control subjects) were low. Functions of the multiple
sclerosis-specific genes were determined based on several sources:
PhosphoSitePlus (http://www.phosphosite.org), NCBI (http://www.
ncbi.nlm.nih.gov/), Panther classification system (http://www.
Figure 1 Continued
Case MS2. Subpial demyelination (F; IHC for PLP) and inflammation in the meninges are seen. The active edge of the lesion is char-
acterized by dense microglia and macrophage infiltration (G; IHC for Iba-1). In the active area with high microglia density, there is also a
diffuse infiltration of CD3-positive T cells into the cortical parenchyma (H; IHC for CD3). Phagocytic macrophages are present and
concentrated at the lesion edge (I; IHC for CD68). (J-M) Cortical lesions in tuberculous meningitis (Case TB3). There is profound
inflammation in the meninges and extensive microglia activation throughout the whole cortex (K; IHC for HLA-D), but cortical myelin
architecture is preserved showing a broad band of myelinated fibres at the subpial surface (indicated by an asterisk in J), low myelin
content in layers 2 and 3 and much higher myelin content in the deeper cortical layers (J; IHC for MBP). In the superficial cortical areas,
which show normal myelin content, there is an extensive tissue infiltration by T cells (L; IHC for CD3) and phagocytic macrophages (M;
IHC for CD68). (N-Q) Cortical lesion from a patient with Rasmussen’s encephalitis (RE1). Despite extensive cortical infiltration by CD8-
positive T cells (P; IHC for CD8), neuronal loss (Bien et al., 2002) and patchy loss of astrocytes (Bauer et al., 2007) (O: IHC for GFAP),
myelin and oligodendrocytes are not affected (N, Q; IHC for CNPase). (R-T) Cortical lesion from a patient with B cell lymphoma (BLY1).
There is profound meningeal, perivascular and parenchymal infiltration by neoplastic B cells (S; IHC for CD20), but the myelin architecture
of the cortex is preserved (R; IHC for MBP). In areas of very dense neoplastic B cell infiltration, myelin is pushed aside by aggregated B
cells, but there is no indication of demyelination (T; IHC for MBP). (U-X) Cortical lesion from a patient with Alzheimer’s disease (AD3).
There are numerous amyloid plaques in the cortex (V; IHC for Aß peptide), but the architecture of cortical myelin is preserved (U; IHC for
PLP). Only in the centre of amyloid plaques (W; IHC for Aß), there is a minor loss of myelin (X; IHC for PLP). MS = multiple sclerosis;
TB = tuberculous meningitis; RE = Rasmussen’s encephalitis; BLY = B cell lymphoma; AD = Alzheimer’s disease; *subpial myelin band.
Scale bar = 100 mm for A–D, F–H, J-O, R, S and U–X; Scale bar = 50 mm for E, I, P, Q and T.
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pantherdb.org), and KEGG Kyoto Encyclopaedia of Genes and Gen-
omes (http://www.genome.jp/kegg). Particularly, PubMed was
screened for genes with known functions in multiple sclerosis or ex-
perimental autoimmune encephalomyelitis.
Based on the microarray data (deposited in NCBI’s Gene Expression
Omnibus; GEO Accession Number GSE32645), genes related to in-
flammation, structural changes, or oxidative injury were selected and
immunohistochemistry was performed on serial sections immediately
adjacent to the sections used for gene expression profiling. For these
exemplary genes, it could be shown that protein expression visualized
by immunohistochemistry followed the up- and down regulation
trends of the microarray data (Supplementary Fig. 1). Furthermore,
TaqMan real-time PCR was performed to validate selected multiple
sclerosis-specific genes (Supplementary Table 4).
Statistical analysis
Descriptive analysis included median value and range, percentages,
scatter plots and box plots. For comparisons of multiple groups, the
Kruskal-Wallis test was used, followed by pair-wise Mann-Whitney
U-tests and Bonferroni-Holm correction. For the analysis of microarray
data (Cases MS1–3 in comparison with all other cases pooled in
one group), Student’s t-tests were performed. The reported P-values
are results of two-sided tests. A P-value 40.05 was considered
statistically significant. Analyses were done using PASW Statistics 18
(SPSS Inc.).
Results
Focal lesions of primary demyelination
are specific for multiple sclerosis
In a first step, we analysed demyelination and neurodegeneration
in the cortex of patients with multiple sclerosis in comparison with
other inflammatory and neurodegenerative diseases. In multiple
sclerosis, cortical pathology was characterized by the presence of
Table 2 Antigen retrieval and primary antibodies
Antibody Origin Target Dilution Antigen
retrieval
Source
Aß Mouse (mAB) Aß peptide 1:500 St (FA or E) MAB1516; Chemicon
AIF Rabbit (pAB) Apoptosis inducing factor 1:250 St (C) AB16501; Chemicon
APP Mouse (mAB) Amyloid precursor protein 1:1000 St (C) MAB348; Chemicon
AQP1 Rabbit (pAB) Aquaporin 1 1:500 0 sc-20810; Santa Cruz
Biotechnoloy
C9neo Rabbit (pAB) Complement component C9 1:2000 P, # Piddlesden et al., 1993
CA II Sheep (pAB) Carbonic anhydrase II 1:1000 St (E) PC076; The Binding Site
Caspase 3 Rabbit (pAB) Activated caspase 3 1:10000 St (C) 551150; BD Biosciences
CB Rabbit (pAB) Calbindin 1:500 St (C) CB-38; SWant Swiss Antibodies
CD3 Rabbit (mAB) T-cells 1:2000 St (E), * RM-9107-S; Neomarkers
CD8 Mouse (mAB) MHC Class I restricted T-cells 1:250 St (E), * M7103; Dako
CD20 Mouse (mAB) B-cells 1:100 St (E) MS-340-S; Neomarkers
CD68 Mouse (mAB) Phagocytic macrophages 1:100 St (E) M0814; Dako
CD163 Mouse (mAB) Macrophage scavenger receptor 1:1000 St (C), * NCL-CD163; Novocastra
CNPase Mouse (mAB) 2’,3’-Cyclic nucleotide 3’ phosphodiesterase 1:2000 St (E) SMI 91; Sternberger Monoclonals
E06 Mouse (mAB) Oxidized phospholipids 10 m/ml 0 or St
(C or E)
Palinski et al., 1996
GFAP Rabbit (pAB) Glial fibrillary acidic protein 1:3000 St (E), + Z0334; Dako
Granzyme B Mouse (mAB) Granzyme B 1:1000 St (E), * MS-1157-S; Neomarkers
HC10 Mouse (mAB) MHC I heavy chain 1:2000 St (E), * Stam et al., 1990
HLA-D Mouse (mAB) Human leucocyte antigen (DP, DQ, DR) 1:100 St (C) M0775; Dako
IBA-1 Rabbit (pAB) Ionized calcium binding adaptor molecule 1 1:3000 St (E) 019-19741; WAKO Chemicals
Ig Sheep (pAB) Human immunoglobulin 1:200 P RPM1003; Amersham
Pharmacia Biotech
iNOS Rabbit (pAB) Inducible nitric oxide synthase 1:30000 St (E), + AB5384; Chemicon
MBP Rabbit (pAB) Myelin basic protein 1:2500 0 A0623; Dako
NF Rabbit (pAB) Neurofilament medium chain (150 kDa) 1:2000 St (E) AB1981; Chemicon
P22phox Rabbit (pAB) NADPH oxidase protein 1:100 St (C), + sc-20781; Santa Cruz
Biotechnology
PECAM-1 Mouse (mAB) Platelet/endothelial cell adhesion molecule-1 1:250 St (E) MS-353; NeoMarkers
PLP Mouse (mAB) Proteolipid protein 1:1000 St (E) MCA839G; Serotec
SY Rabbit (mAB) Synaptophysin 1:100 St (C) 1485-1; Epitomics
TPPP/p25 Rat (pAB) Tubulin polymerization promoting protein 1:3000 St (E) Hoftberger et al., 2010
0 = no antigen retrieval; St = steaming of sections using the indicated buffer solution; C = citrate buffer (pH 6.0); E = EDTA buffer (pH 9.0); P = protease predigestion;
FA = formic acid; mAB = monoclonal antibody; pAB = polyclonal antibody; * = 3,3’-diaminobenzidine development enhanced by biotinylated tyramine amplification (King
et al., 1997); # = antibody labelling visualized with 3-amino-9-ethylcarbazole instead of routinely used 3,3’-diaminobenzidine; + = antibody labelling visualized with Fast
blue B instead of routinely used 3,3’-diaminobenzidine.
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large plaques of primary demyelination (complete loss of myelin
with axonal preservation such as preservation of phosphorylated
neurofilament-reactive profiles) as described previously (Peterson
et al., 2001; Kutzelnigg et al., 2005). In one case of secondary
progressive multiple sclerosis (Case MS1), fulminate inflammatory
cortical lesions were present, similar to those described in early
multiple sclerosis (Lucchinetti et al., 2011) with profound inflam-
mation in the meninges (Fig. 1B), abundant perivascular inflam-
matory cuffs (Fig. 1D and Supplementary Fig. 1) and T and B
lymphocyte infiltration into the cortical parenchyma (Fig. 1C and
Supplementary Table 1). Active cortical demyelination (Fig. 1A)
was reflected by the presence of activated macrophages contain-
ing myelin degradation products reactive for PLP (Fig. 1E). The
other multiple sclerosis cases (shown representatively by Case MS2
in Fig. 1F–I) exhibited cortical demyelinated lesions as described
(Howell et al., 2011). In these expanding cortical lesions, lympho-
cyte infiltration was restricted to the meninges and the zones of
lesional activity. A variable degree of microglia activation was
observed, forming a band of high cell density at the margin to-
wards the normal appearing grey matter (see Supplementary
Fig. 1). In these areas, few diffusely dispersed T cells were present
(Fig. 1H) and microglia cells contained myelin degradation
products.
Cortical lesions in patients with tuberculous or luetic meningitis
also showed strong meningeal and parenchymal inflammation
with a similar cellular composition of T cells, B cells, plasma
cells, and macrophages as in multiple sclerosis (Fig. 1K–M). In
some cases, the infiltrates additionally contained granulocytes.
Despite the massive inflammatory reaction in the cortex, no
focal primary plaque-like demyelination was present (Fig. 1J).
Cortical lesions from patients with Rasmussen’s encephalitis (a
paradigmatic example of encephalitis mediated by MHC class I
restricted T cells) showed only minor meningeal inflammation,
dominated by T cells and macrophages, but profound diffuse T
cell infiltration of the cortical parenchyma (Fig. 1P). These infil-
trates were associated with massive microglia activation and neur-
onal and astrocytic degeneration (Fig. 1O) (Bien et al., 2002;
Bauer et al., 2007). Again, no indication for focal multiple scler-
osis-like primary demyelination was found (Fig. 1N and Q).
In B cell lymphomas affecting the cortex, massive infiltration of
the meninges and the cortical parenchyma by neoplastic B cells
(Fig. 1S) and a variable extent of T cell infiltration and microglia
activation were seen. In severely affected regions, this resulted in
displacement of the cortical parenchyma by neoplastic cells. In
areas of very dense B cell infiltration, myelin was pushed aside
by aggregated B lymphocytes (Fig. 1T), but there was no indica-
tion of primary demyelination (Fig. 1R).
No plaque-like demyelination was present in the cortex of pa-
tients with Alzheimer’s disease (Fig. 1U). However, immunohisto-
chemistry for proteolipid protein revealed a minor loss of myelin
within the core and the vicinity of amyloid plaques (Fig. 1V–X)
(Mitew et al., 2010).
These data indicate that the formation of plaque-like primary
demyelinating cortical lesions is multiple sclerosis-specific and does
not simply reflect tissue damage induced by inflammatory mech-
anisms or mediators.
Comparative analysis of gene
expression in cortical lesions
Quantitative immunohistochemistry (Table 3) of disease and con-
trol cases selected for our microarray study confirmed that inflam-
mation mediated by T cells, B cells, and microglia activation were
most pronounced in tuberculous meningitis, whereas demyelin-
ation and oligodendrocyte loss were restricted to multiple sclerosis
lesions. Neuronal and axonal injury was present in multiple scler-
osis, tuberculous meningitis, and Alzheimer’s disease, but was
highest in multiple sclerosis compared with the other diseases.
Analysing our microarray data, we found 109 genes significantly
up- or downregulated in multiple sclerosis in comparison with all
other disease and control cases (P50.01; Supplementary
Table 2). In a separate approach, we examined gene expression
in Case MS1, which presented with fulminate inflammatory cor-
tical demyelination. Comparing this single multiple sclerosis case
with all other cases included in our gene expression study allowed
us to specifically examine the inflammatory component of this
active cortical lesion. As a restrictive cut-off point we chose
genes that were differentially up- (44-fold log2) or downregu-
lated (54.5-fold log2) compared with all other cases, including
tuberculous meningitis cases showing the highest extent of inflam-
mation. This resulted in 192 hits (144 upregulated and 48 down-
regulated; Supplementary Table 3). Taking together the two
analysis approaches, we identified 301 multiple sclerosis-specific
genes. Among those genes, 82% could be grouped into three
major categories (Fig. 2 and Supplementary Tables 2 and 3): in-
flammation and immune cell activation/migration (24%), oxidative
injury, DNA damage/repair, and cell death (28%), and tissue
repair/regeneration (52%). Assignment of genes to multiple cate-
gories was tolerated. A comprehensive tabular summary of all
multiple sclerosis-specific genes including log2 fold-changes, P-
values, gene accessions and gene functions, can be found in
Supplementary Tables 2 and 3.
Category 1: genes associated with
inflammation
Differential expression of inflammation-associated genes was
mainly seen in the highly inflammatory cortical lesions of Case
MS1 (Supplementary Table 3). Functional grouping revealed that
many of the identified genes code for proteins involved in antigen
recognition of class I and class II restricted T cells and in the regu-
lation of Th1 and Th17 T-cell responses (10 genes), in microglia
and macrophage function (seven genes), and in chemokine/cyto-
kine signalling and leucocyte recruitment (18 genes). Profound
multiple sclerosis-specific changes were also seen for genes
involved in synthesis and function of selectins.
Category 2: genes associated with cell
death, DNA damage and DNA repair
The most prominent changes in gene expression (Fig. 2, Table 4,
Supplementary Tables 2 and 3) were found for genes involved in
different steps of apoptosis, DNA damage, p53 function and DNA
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repair (Table 4). They also included potassium and chloride chan-
nels controlling cell volume in the course of cell body or cell pro-
cess degeneration, or genes involved in the modulation of
excitotoxic or ischaemic cell death. This was in line with the iden-
tification of another cluster of genes with multiple sclerosis-specific
expression, which was related to hypoxia, oxidative stress and
mitochondria (Table 4).
Category 3: reaction to tissue injury and
association with tissue repair
This category constituted the largest one (Fig. 2, Table 5, Supple-
mentary Tables 2 and 3). A major subgroup included genes coding
for proteins involved in RNA metabolism or regulation of
transcription or translation. Another considerable cluster was
related to development in general and to brain development in
particular. It comprised genes necessary for various cellular func-
tions such as cell survival, growth, and differentiation or control of
cytoskeletal components (in particular tubulin turnover). One fur-
ther group contained genes functionally associated with axonal
and synaptic biology and regeneration (Table 5). The majority of
these were either involved in axonal growth and guidance, or in
synapse function. As expected, we also found significantly
increased expression of some myelin- and oligodendrocyte-related
genes in multiple sclerosis. Their expression was highest in Cases
MS2 and MS3, which contained demyelinated and remyelinating
lesion centres with rims of active demyelination at the border to
the white matter.
Figure 2 Based on their known functions, multiple sclerosis-specific genes can be grouped into three major categories. Summary of
differentially expressed genes in multiple sclerosis lesions compared with tuberculous meningitis, Alzheimer’s disease and control cortex.
The genes are grouped according to their possible functions into inflammation-, tissue injury- and regeneration-related genes. Detailed
lists of the differentially expressed genes are provided in Supplementary Tables 2 and 3. Potential molecular pathways of tissue injury are
summarized in the lower half of the figure. The most important multiple sclerosis-specific genes concerning tissue injury and regeneration
are listed in Tables 4 and 5. ROS/NOS = reactive oxygen species/nitric oxide synthase.
Table 3 Inflammation and tissue injury in the cortices of cases selected for microarray analysis
Multiple sclerosis (n = 3) Tuberculous
meningitis (n = 3)
Alzheimer’s
disease (n = 3)
Controls
(n = 3)
T cells 91 (55) 541 (860) 11 (9) 11 (24)
Microglia/macrophages 757 (596) 2301 (1449) 552 (218) 544 (252)
Extent of demyelination 41 (23) 1 (1) 0 (0) 0 (0)
Oligodendrocytes 23 (14) + / 105 (52)# 50 (32) 82 (23) 67 (107)
Neurons 154 (70) + / 221 (60)# 214 (24) 198 (43) 235 (15)
Axonal spheroids 8 (93) + / 6 (30)# 3 (7) 8 (26) 0 (2)
This table summarizes the quantification of immunohistochemical results to determine the levels of inflammation, demyelination, and neurodegeneration in disease cases
selected for microarray analysis. CD3-positive T cells, CD68-positive microglia/macrophages, TPPP/p25-positive oligodendrocytes, neurons and neurofilament-reactive
dystrophic axons were counted (counts/mm2). The extent of demyelination was calculated as demyelinated area in relation to total cortex area. Results are presented as
median value and range (in brackets). + = lesion centre; # = lesion edge.
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Table 4 Microarray analysis: most important genes regarding tissue injury
Gene symbol Gene name (gene function) Log2 P-value
Reactive oxygen species/nitric oxide synthase
GGTLC1 Gamma-glutamyltransferase light chain 1 (glutathione metabolism) 5.70
DDAH2 Dimethylarginine dimethylaminohydrolase 2 (NOS synthesis) 5.54
TXNIP Thioredoxin interacting protein (increases production of ROS) 4.76
SMOX Spermine oxidase (radical scavenger) 4.38
GSTT1 Glutathione S-transferase theta 1 (antioxidant) 4.07
OGDHL Oxoglutarate dehydrogenase-like (oxidoreductase) 2.77 50.001
ARHGEF18 Rho/rac guanine nucleotide exchange factor 18 (ROS production) 2.28 0.001
HP Haptoglobin (cellular iron ion homeostasis) 2.01 0.005
ASPHD1 Aspartate beta-hydroxylase domain containing 1 (oxidoreductase) 1.48 0.001
NOS1AP Nitric oxide synthase 1 adaptor protein (neuronal nitric oxide synthesis) 0.91 0.009
NAPRT1 Nicotinate phosphoribosyltransferase domain containing 1 (oxidative stress response) 0.88 0.005
Excitotoxicity/ischaemia
CLCA1 Chloride channel, calcium activated, family member 1 (NMDAR-induced ischemic cell
death)
6.91
SLC8A1 Solute carrier family 8 (sodium/calcium exchanger), member 1 (protective role in
ischemia)
5.39
ACMSD Aminocarboxymuconate semialdehyde decarboxylase (may inhibit excitotoxicity) 4.91
CACNA1E Calcium channel, voltage-dependent, R type, alpha 1E subunit (protective role in
ischemia)
5.13
Hypoxia
OS9 Amplified in osteosarcoma (binds and inactivates HIF1) 4.81
CITED4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4
(inhibits HIF1 signalling)
0.90 0.009
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
(negative regulator for HIF1)
4.54
HSD11B2 Hydroxysteroid (11-beta) dehydrogenase 2 (response to hypoxia) 4.55
USP20 Ubiquitin specific peptidase 20 (deubiquitinates HIF1) 4.74
Mitochondrial injury
SLC25A4 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator),
member 4 (exchange of cytoplasmic ADP with mitochondrial ATP)
5.96
PYCR1 Pyrroline-5-carboxylate reductase 1 (NADP + generation) 5.31
ND6 NADH-ubiquinone oxidoreductase chain 6 (mitochondrial respiratory chain) 5.07
TSFM Ts translation elongation factor, mitochondrial (translation of mitochondrial proteins) 2.04 0.006
p53 signalling
ZMIZ1 Zinc finger, MIZ-type containing 1 (coactivator of p53) 5.34
RNF144B Ring finger 144B (induces p53-dependent cell death) 4.77
P2RX6 P2X purinoceptor 6 (p53 responsive gene) 4.30
IGFBP7 Insulin-like growth factor binding protein 7 (p53 responsive gene) 4.21
CUL9 p53-associated parkin-like cytoplasmic protein (regulation of p53 localization) 2.14 0.007
ZNHIT1 Zinc finger, HIT type 1 (induces p53-mediated apoptosis) 1.76 0.008
BRD7 Bromodomain containing 7 (p53 interactor) 1.43 0.005
MEG3 Maternally expressed 3 (p53 interactor) 0.97 0.009
PSRC1 Proline/serine-rich coiled-coil 1 (p53-regulated growth suppression) 4.54
ZNF668 Zinc finger protein 668 (p53 regulation) 5.92
DEC1 Deleted in esophageal cancer 1 (p53-dependent senescence) 8.99
DNA damage
DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide (DNA fragmentation during
apoptosis)
4.95
DNA repair
RAD51 RAD51 homolog (repair of DNA double strand breaks) 6.06
ERCC5 Excision repair cross-complementing rodent repair deficiency, complementation group
5 (nucleotide excision repair)
5.28
LIG1 Ligase I, DNA, ATP-dependent (base excision repair and DNA replication) 0.98 0.009
WRNIP1 Werner helicase interacting protein 1 (initiation of DNA synthesis) 4.87
Apoptosis
BMF Bcl2 modifying factor (proapoptotic) 7.53
TMEM16G Transmembrane protein 16G (may function during apoptotic cell death) 4.74
PACS2 Phosphofurin acidic cluster sorting protein 2 (induces mitochondrial cytochrome C
release)
4.69
(continued)
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Increased oxidative damage and DNA
strand breaks in cortical multiple
sclerosis lesions compared with
tuberculous meningitis and other
controls
So far, our microarray data suggested multiple sclerosis-specific
changes in the expression of genes related to oxidative injury
and DNA damage in cortical lesions. We therefore attempted to
confirm these data in the entire sample or cases with multiple
sclerosis listed in Table 1. From the individual cases with multiple
sclerosis, cortical lesions were selected, which contained a demye-
linated area with oligodendrocyte loss, surrounded by an area of
microglia activation with interspersed macrophages containing
early tissue degradation products and an adjacent area of
normal appearing grey matter. In comparison with control cortices,
a significant loss of neurons (31.1% loss; P50.01) was seen in
the demyelinated areas of multiple sclerosis cortex, which is in the
range of that described previously (Vercellino et al., 2005; Wegner
Table 4 Continued
Gene symbol Gene name (gene function) Log2 P-value
ASAH2 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 (blocks ceramide-
induced apoptosis)
4.68
HRASLS3 HRAS-like suppressor 3 (involved in interferon-induced cell death) 4.00
MAP3K10 Mitogen-activated protein kinase kinase kinase 10 (nerve growth factor- induced neur-
onal apoptosis)
3.28 0.001
TMEM16H Transmembrane protein 16H (may function during apoptotic cell death) 2.70 50.001
PRKCZ Protein kinase C, zeta (Fas ligand-induced apoptosis) 2.55 0.004
TNFAIP1 Tumor necrosis factor, alpha-induced protein 1 (proapoptotic) 2.38 0.002
PKD1 Polycystic kidney disease 1 (proapoptotic) 2.11 0.004
TRADD TNFRSF1A-associated via death domain (proapoptotic) 1.67 0.004
CMTM5 CKLF-like MARVEL transmembrane domain containing (induces apoptosis in synergy
with TNF)
1.52 50.001
WISP1 WNT1 inducible signaling pathway protein 1 (attenuates apoptosis) 5.94
Genes of both microarray analysis approaches are included. For Comparison 1 [significantly (P50.01) changed genes in Cases MS1–3 in comparison with all other cases
(Cases TB1–3, AD1–3 and CO1–3; n = 9)], log2 fold-changes as well as the corresponding P-values are shown. For Comparison 2 [massively up- or downregulated genes
(log2 fold-changes44 or54.5, respectively) in Case MS1 in comparison with all other cases], only the log2-transformed fold-changes are given. A complete gene list is
provided in Supplementary Tables 2 and 3. NOS = nitric oxide synthase; ROS = Reactive oxygen species.
Table 5 Microarray analysis: most important genes regarding the regeneration of neuronal processes
Gene symbol Gene name (gene function) Log2 P-value
GPM6A Glycoprotein M6A (neuronal differentiation; neurite outgrowth; neuronal plasticity) 6.10
PHF10 PHD finger protein 10 (dendrite growth) 5.71
CACNB2 Calcium channel, voltage-dependent, beta 2 subunit (axon guidance; synaptic transmission) 5.63
TNN Tenascin N (axon repulsion) 5.48
NEO1 Neogenin homolog 1 (axon guidance) 4.12
ANKS3 Ankyrin repeat and sterile alpha motif domain containing 3 (axon guidance) 4.03
CARTPT CART prepropeptide (neuronal development) 2.54 0.000
LRFN2 Leucine rich repeat and fibronectin type III domain containing 2 (dendrite outgrowth; synapse formation) 1.79 0.000
MYLK2 Myosin light chain kinase 2 (synaptic plasticity) 1.50 0.001
SLIT1 Slit homolog 1 (axon guidance) 1.47 0.003
SORL1 Sortilin-related receptor, L(DLR class) A repeats-containing (discussed for axon regeneration) 1.42 0.003
TRIM2 Tripartite motif-containing 2 (axon outgrowth) 1.25 0.003
STMN3 Stathmin-like 3 (neurite development) 1.23 0.009
ISLR2 Immunoglobulin superfamily containing leucine-rich repeat 2 (axon outgrowth) 0.94 0.007
CAMK2B Calcium/calmodulin-dependent protein kinase (CaM kinase) II beta (plasticity of glutamatergic synapses) 4.60
ACTL6B Actin-like 6B (neuronal development; dendrite morphogenesis) 4.85
SEMA6B Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B (axon guidance) 5.39
Genes of both microarray analysis approaches are included. For Comparison 1 [significantly (P5 0.01) changed genes in Cases MS1–3 in comparison with all other cases
(TB1–3, AD1–3, and CO1–3; n = 9)], log2 fold-changes as well as the corresponding P-values are shown. For Comparison 2 [massively up- or downregulated genes (log2
fold-changes44 or54.5, respectively) in MS1 in comparison with all other cases], only the log2-transformed fold-changes are given. A complete gene list is provided in
Supplementary Tables 2 and 3.
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et al., 2006; Magliozzi et al., 2010; Choi et al., 2012) and in the
cortices of Alzheimer’s disease (40%; P50.001; Supplementary
Fig. 2). Our previous studies of active white matter lesions (Haider
et al., 2011; Fischer et al., 2012) indicated that immunohisto-
chemistry for oxidized phospholipids (E06 immunoreactivity) is a
sensitive marker for degenerating oligodendrocytes and dystrophic
axons. In cortical multiple sclerosis lesions, we observed a similar
immunoreactivity for oxidized phospholipids in the mentioned cell
types, concentrated at sites of ongoing demyelination (Fig. 3A and
M). Neurons with intense cytoplasmic accumulation of oxidized
phospholipids (Fig. 3N) were significantly more abundant in
active cortical multiple sclerosis lesions than in lesions of tubercu-
lous meningitis, luetic meningitis, chronic purulent meningitis
(P50.05), Alzheimer’s disease (P5 0.05) or controls
(P50.001; Figs 3A–D and 4A). In addition, oxidatively damaged
neurons showed process fragmentation (Fig. 3E–H, O and P) or
nuclear changes of necrosis- or apoptosis-like cell death as defined
earlier (Muller et al., 2004) (Fig. 3I and J). Furthermore, nerve cells
exhibiting central chromatolysis, a sign of proximal axon transec-
tion, also showed profound E06 immunoreactivity (Fig. 3K and L).
Additionally, we performed TUNEL staining for DNA strand
breaks. TUNEL-positive nuclei of neurons and oligodendrocytes
were most frequently seen in multiple sclerosis lesions in the
areas of active demyelination and tissue injury (Fig. 3R), whereas
their number was much smaller in the demyelinated lesion centre
and the normal appearing grey matter (Fig. 4B). Few TUNEL-posi-
tive nuclei were seen in the cortex of controls or patients with
tuberculous meningitis (Figs 3S and 4B). Double staining for
TUNEL and oxidized phospholipids showed that neurons with
oxidative damage either contained condensed nuclei with high
TUNEL reactivity, suggestive for apoptosis (Fig. 3U), or nuclei
with small focal spots of damaged DNA (Fig. 3T).
Immunohistochemistry for activated caspase 3 was negative
throughout the whole tissue sample, suggesting caspase-inde-
pendent cell death (data not shown). Apoptosis inducing factor
was present in the mitochondria of healthy neurons in control
and multiple sclerosis tissue (Fig 3V). In active multiple sclerosis
lesions, however, neurons were seen, which in addition to mito-
chondrially located apoptosis inducing factor also showed diffuse
apoptosis inducing factor immunoreactivity in the cytoplasm and
presence of apoptosis inducing factor in cell nuclei (Fig. 3W).
Cells with cytoplasmic accumulation of oxidized phospholipids
were mainly present in cortical areas with high density of activated
microglia expressing the NADPH oxidase component p22phox
(Fig. 5A). Processes of p22phox-positive microglia were attached
either to the cell body (Fig. 5B) or to dendrites of neurons with
oxidative injury (Fig. 5C). Immunohistochemistry for inducible
nitric oxide synthase (iNOS) revealed that active cortical multiple
sclerosis lesions contain only few inducible nitric oxide synthase-
reactive cell bodies or processes of microglia (Fig. 5D).
Macrophages with high inducible nitric oxide synthase immunor-
eactivity were seen in more advanced white matter lesions
(Fig. 5E). These findings are in line with our microarray results
showing an up-regulation of certain NADPH oxidase subunits
(mainly components of NOX1 and NOX2 complexes) in cortical
multiple sclerosis lesions in comparison with tuberculous meningitis
or control cases (Fig. 5F).
Discussion
Active cortical demyelination and neurodegeneration in multiple
sclerosis are associated with inflammation in the cortical tissue
itself (Lucchinetti et al., 2011) or in the meninges (Kutzelnigg
et al., 2005; Howell et al., 2011). It has thus been suggested
that tissue injury is either mediated by inflammatory cells or
their soluble mediators diffusing into the cortex and inducing
tissue damage either directly or indirectly through microglia acti-
vation (Howell et al., 2011). Several types of inflammatory cells,
including T cells or B cells, are regarded as particularly important in
multiple sclerosis pathogenesis and thought to trigger demyelin-
ation and neurodegeneration in a non-specific ‘bystander’ fashion
(Wisniewski and Bloom, 1975). A previous study (Moll et al.,
2008) indicated that cortical demyelination may be multiple scler-
osis-specific, but this conclusion was based on diseases with in-
flammatory reactions quite different from multiple sclerosis. In our
study, we confirm this view by focusing on diseases, which to our
knowledge more closely reflect key inflammatory components
operating in multiple sclerosis lesions. Thus, demyelination and
neurodegeneration in multiple sclerosis are not unspecific conse-
quences of inflammation, but appear to involve multiple sclerosis-
specific mechanisms of tissue injury.
Microarray studies have been performed on cortical tissue of
multiple sclerosis before. They revealed changes related to mito-
chondrial function in the non-demyelinated motor cortex (Dutta
et al., 2006), to axonal transport and synaptic function (Dutta
et al., 2011), to the regulation of oligodendrocyte differentiation
(Schmidt et al., 2012) and to intrathecal immunoglobulin synthesis
(Torkildsen et al., 2010). In contrast to our current study, they
focused on normal appearing grey matter or demyelinated areas,
but not on areas of active demyelination and tissue injury.
Furthermore, they did not include other disease controls. Thus,
the prominent expression of immunoglobulin related genes
described by Torkildsen et al., (2010) did not appear in our results,
because tuberculous meningitis, similar to multiple sclerosis, shows
profound intrathecal immunoglobulin synthesis.
Our results showed multiple sclerosis-specific gene expression
changes in mainly three different molecular pathways: inflamma-
tion, oxidative stress associated with DNA damage, and regenera-
tive mechanisms affecting oligodendrocytes, neurons and neuronal
cell processes.
Multiple sclerosis-specific gene expression related to inflamma-
tion (Supplementary Tables 2 and 3) involved molecules important
for antigen presentation and polarization of MHC class I and II
restricted T cells towards Th1 and Th17 pathways (Tzartos et al.,
2008) or macrophage/microglia activation. Downregulation of the
expression of the co-stimulatory molecule CTLA4 in active cortical
lesions (Supplementary Table 3) is in agreement with the proposed
anti-inflammatory function of this molecule in patients with mul-
tiple sclerosis (Joller et al., 2012). Results supporting our current
data have been reported before in other gene expression studies
(Whitney et al., 1999; Lock et al., 2002; Mycko et al., 2003) and
interpretation of the data is in agreement with inflammatory path-
ways identified in genome-wide association studies on multiple
sclerosis susceptibility (Sawcer et al., 2011). Our study further
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Figure 3 Cytoplasmic accumulation of oxidized phospholipids (E06 reactivity) in cortical multiple sclerosis lesions. (A–D) Cortical tissue
from multiple sclerosis (A; MS1), tuberculous meningitis (B; TB2), and Alzheimer’s disease (C; AD2) patients and control (D; CO3) cases.
Numerous cells with strong cytoplasmic E06 immunoreactivity are seen in the multiple sclerosis cortex (A), while only sparse E06-positive
cells are seen in the other conditions (B–D). However, some granular, lipofuscin-like E06 immunoreactivity is visible mainly within neurons
and macrophages in all examined cases. (E–H) Neurons with extensive cytoplasmic accumulation of oxidized phospholipids show beading
and fragmentation of their processes in active cortical multiple sclerosis lesions. (I and J) Patterns of degeneration (Muller et al., 2004) in
neurons with extensive accumulation of oxidized phospholipids. Neurons with numerous fine speckles of condensed chromatin resembling
1810 | Brain 2013: 136; 1799–1815 M. T. Fischer et al.
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identified a number of molecules that are instrumental in leucocyte
trafficking into inflammatory lesions including integrin alpha 9, a
binding partner of vascular cell adhesion molecule (VCAM).
Blockade of VCAM/integrin interaction is currently a very effective
anti-inflammatory treatment in patients with multiple sclerosis
(Polman et al., 2006). Our results also indicate that selectins,
which mediate inflammation in peripheral organs and the brain
through integrin activation (Prendergast and Anderton, 2009;
Alvarez et al., 2011; Zarbock et al., 2012), may play a role in
regulating leucocyte trafficking in cortical multiple sclerosis lesions
in the progressive stage of the disease. High expression of some
selectins has also been shown before in microarray studies on
microdissected blood vessels from patients with multiple sclerosis
(Cunnea et al., 2010).
Regarding mechanisms of tissue injury, which were in the main
focus of our study, our results suggest that oxidative damage plays
a major role in the processes of cortical oligodendrocyte degener-
ation, demyelination and neuronal damage. These resemble mech-
anisms observed previously in active white matter lesions and
adjacent normal appearing white matter. Expression of enzymes
involved in oxygen (Gray et al., 2008; Fischer et al., 2012) and
nitric oxide radical production (Liu et al., 2001; Marik et al., 2007;
Zeis et al., 2009), the abundance of oxidized lipids and DNA in
degenerating oligodendrocytes and axons (Haider et al., 2011),
the increased expression of molecules involved in antioxidant de-
fence (van Horssen et al., 2008) and the presence of hypoxia-like
tissue injury in active lesions and the adjacent normal appearing
white matter (Aboul-Enein et al., 2003; Graumann et al., 2003;
Trapp and Stys, 2009) have been shown before. Oxidative stress is
assumed to lead to mitochondrial injury in multiple sclerosis lesions
(Dutta et al., 2006; Mahad et al., 2008; Campbell et al., 2011;
Lassmann et al., 2012). Here we show that immunoreactivity for
oxidized phospholipids is much higher in neurons of active cortical
multiple sclerosis lesions than in all other conditions studied (tu-
berculous meningitis, Alzheimer’s disease, and control subjects).
Furthermore, the expression of genes involved in DNA damage
and repair was highly up-regulated in multiple sclerosis lesions
in comparison with other inflammatory or neurodegenerative
controls such as tuberculous meningitis or Alzheimer’s disease
(Table 4, Supplementary Tables 2 and 3). This was also confirmed
by the much higher incidence of cells with TUNEL reactivity in
areas of active demyelination and tissue injury. TUNEL reactivity,
which has been shown before to occur in low incidence in inactive
cortical multiple sclerosis lesions (Peterson et al., 2001), may re-
flect apoptotic cell death, but also reversible DNA injury. In line
with previous studies, apoptosis in multiple sclerosis lesions was
not associated with caspase 3 activation (Barnett and Prineas,
2004), but with the liberation of apoptosis inducing factor from
mitochondria and its nuclear translocation (Veto et al., 2010).
Neuronal cell death within active lesion areas may at least in
part be responsible for neuronal loss in established lesions.
The mechanisms that drive oxidative injury and neurodegenera-
tion in multiple sclerosis lesions are currently not fully understood.
Persistent inflammation in meninges and cortical parenchyma ap-
pears to be one important driving force (Howell et al., 2011; Choi
et al., 2012; Lucchinetti et al., 2011). In addition, factors related
to ageing and to chronicity of the disease may play a role. As an
example, age-related iron accumulation in the human brain may
amplify oxidative injury (Lassmann et al., 2012). Furthermore, it
was shown in a recent study that the topography of cortical le-
sions may be related to distant lesions within the white or deep
grey matter (Kolasinski et al., 2012), indicating a role of antero-
grade or retrograde degeneration in the precipitation of cortical
lesions. This may also in part explain the differences between cor-
tical lesions in multiple sclerosis and tuberculous meningitis, the
latter exposing the cortex to inflammation in the absence of
pre-existing distant neurodegeneration.
An interesting observation of our study is that oxidative injury of
neurons in the multiple sclerosis cortex coincides with beading and
fragmentation of axons and dendrites. Degeneration of neuronal
processes was present in cells, in which the peri-nuclear cell body
remained morphologically intact. This is further supported by our
microarray analyses comprising many genes related to axonal,
dendritic, and synaptic regeneration. A similar result has been ob-
tained in previous work analysing gene expression in hippocampal
multiple sclerosis lesions (Dutta et al., 2011), and it was suggested
that the profound axonal injury in cortical multiple sclerosis lesions
is related to increased vulnerability of demyelinated axons
Figure 3 Continued
‘necrosis-like’ cell death (I) as well as neurons with large fragments of condensed chromatin resembling ‘apoptosis-like’ cell death (J) can
be found. (K and L) Neurons with central chromatolysis as a reaction to proximal axonal transsection show intense reactivity for oxidized
phospholipids. (M) E06 reactivity in oligodendrocytes in active cortical multiple sclerosis lesion of Case MS1. The figure shows two normal
oligodendrocytes (white arrows), one oligodendrocyte with accumulation of oxidized phospholipids (white arrowhead) and an astrocyte
(white asterisk). Triple antibody labeling for E06 (green), carboanhydrase (red), and glial fibrillary acidic protein (blue). (N) Calbindin-
positive nerve cell in a cortical multiple sclerosis lesion with cytoplasmic E06 immunoreactivity. Double antibody labelling for E06 (green)
and calbindin (red). (O and P) Double staining for E06 (green) and neurofilament (red) shows individual dystrophic axons with E06
immunoreactivity. (Q) Double staining for E06 (green) and synaptophysin (red) shows a neuron with oxidized phospholipids, but no E06
immunoreactivity in synaptophysin-positive synapses.(R) Cortical lesion of Case MS1 stained for DNA strand breaks with TUNEL (black
nuclei); the number of nuclei with DNA strand breaks is similar to the number of cells stained for oxidized phospholipids, shown in A.
(S) TUNEL staining of control cortex (CO3); no nuclear TUNEL reactivity is seen. (T and U) Double staining for TUNEL (black) and E06
(red) shows either spotted TUNEL reactivity in E06 positive neurons with otherwise intact nuclei (T) or intense TUNEL reactivity in neurons
with condensed apoptotic like nuclei (U). (V and W) Apoptosis inducing factor immunoreactivity is present in a staining pattern resembling
mitochondria in normal neurons (V), but in addition shows diffuse cytoplasmic staining and nuclear reactivity in neurons with beaded cell
processes (W). Scale bars: A–D = 100 mm; E–Q and T–W = 50 mm; R and S = 200 mm.
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(Dutta et al., 2011). Our study proposes an additional mechanism:
direct oxidative injury and focal damage of axons and dendrites
due to the primary destructive events. Partial repair of neuronal
cell processes in cortical multiple sclerosis lesions may occur in
parallel with remyelination (Albert et al., 2007) and may be asso-
ciated with functional plasticity seen in MRI studies (Rocca and
Filippi, 2007; Caramia et al., 2010).
We are aware that our study has limitations regarding the ana-
lysis of whole-genome microarrays. RNA was isolated from for-
maldehyde-fixed and paraffin-embedded material, which is known
to be inferior in comparison with fresh frozen tissue. Eisele et al.
(2012) published a comprehensive study comparing formalde-
hyde-fixed and paraffin-embedded to fresh frozen material
using, among others, tissue derived from our archives. Eisele
et al. (2012) showed that although integrity measurements of
RNA isolated from formaldehyde-fixed and paraffin-embedded
material resulted in very low integrity numbers, amplicons with a
length of 5150 bp were still detectable. Eisele et al. (2012) per-
formed quantitative PCR-based transcript profiling analysing the
expression of 84 extracellular matrix-related genes and identified
a transcript loss of 47% in formaldehyde-fixed and paraffin-
embedded-derived samples in comparison with fresh frozen ma-
terial. Of course, such false negative results can be expected in our
study as well. We tried to minimize this problem accordingly by
first of all using only tissue blocks that showed reasonable RNA
preservation, as evidenced by strong in situ hybridization signals
after a short time of development. Secondly, stringent RNA quality
criteria were applied to ensure that only samples with sufficiently
long RNA fragments were further processed. Thirdly, we used
whole-genome microarrays from Agilent. As shown in
Supplementary Table 4, most of the probes of Agilent arrays
were located within the last exon. Because the RNA fragments
contained in our samples were amplified using poly(A) tail primers,
the binding probability to the corresponding microarray probes
was maximized. Fourthly, we focused on either highly significantly
changed genes (P50.01) or used restrictive cut-offs (log2 fold-
changes 44 or 54.5). Additionally, we did not focus on single
gene analysis, which would require much more stringent molecular
and biochemical confirmation of the identified molecules. Instead,
we used the microarray data for the identification of intercon-
nected pathways within specific and extremely well characterized
lesions. The involvement of these pathways in multiple sclerosis
pathology, but not necessarily the involvement of single pathway-
revealing molecules, was then evaluated in immunohistochemical
analyses using a much larger sample of cases and lesions. We
want to point out that our microarray analyses also included a
single case comparison (Case MS1 in comparison with all other
cases). This was done, since this case showed an extreme degree
of cortical inflammatory demyelinating activity, which is extremely
rare in multiple sclerosis tissue available for pathological analysis
(Kutzelnigg et al., 2005; Lucchinetti et al., 2011) and for this
reason may be particularly informative with respect to the ques-
tions addressed in this study. Despite these limitations, a strong
argument for the validity of our data is the fact that 480% of
Figure 4 Neurons with intense cytoplasmic accumulation of oxidized phospholipids and DNA strand breaks are abundant in active cortical
multiple sclerosis lesions. (A) Scatter plot displaying the percentage of neurons with intense, cytoplasmic E06 immunoreactivity in relation
to the total number of counted cortical neurons. In active multiple sclerosis lesion areas, significantly more oxidatively damaged neurons
are present in comparison with other inflammatory diseases (tuberculous meningitis/luetic meningitis/chronic purulent meningitis;
P50.05), neurodegenerative diseases (Alzheimer’s disease; P50.05), or control cases (P5 0.001). The median value for each group is
indicated by a grey bar. (B) Scatter plot of TUNEL-positive nuclei in the cortex of patients with multiple sclerosis in comparison with that of
tuberculous meningitis, Alzheimer’s disease and control subjects. Cells with DNA strand breaks are mainly present in the area of lesional
activity in patients with multiple sclerosis (multiple sclerosis edge). NAGM = normal appearing grey matter; MS = multiple sclerosis;
TB = tuberculous meningitis; LM = luetic meningitis; ME = chronic purulent meningitis; AD = Alzheimer’s disease; CO = control;
*P5 0.05; ***P5 0.001.
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Figure 5 Oxidative damage in cortical multiple sclerosis lesions is mainly driven by NADPH oxidases. (A–C) Cells containing oxidized
phospholipids (brown) are located in areas with numerous microglia expressing the NADPH oxidase component p22phox (blue).
P22phox-positive, activated microglia embrace oxidatively damaged neurons with their processes (B) or are in contact with neuronal
cell processes (C). (D and E) Double labelling for E06 (brown) and inducible nitric oxide synthase (iNOS; blue). Cortical multiple sclerosis
lesions with profound cellular accumulation of oxidized phospholipids contain only few microglia cells or processes reactive for inducible
nitric oxide synthase (D). In contrast, macrophages with high immunoreactivity for inducible nitric oxide synthase are seen in more
advanced lesions in the white matter of the same section (E). (F) The heat map presents colour-coded log2-transformed fold-changes of
genes coding for NADPH oxidase components or nitric oxide synthase enzymes. For this analysis, the fulminate Case MS1 was compared
with either tuberculous meningitis (TB1–3; left column) or controls (CO1–3; right column). The comparisons are in line with immuno-
histochemical studies suggesting oxidative damage to be driven by NOX1 and NOX2 components of NADPH oxidases and not by nitric
oxide synthaseenzymes. The colour gradient was computed using 10th, 50th, and 90th percentiles. Green, black and red colours indicate
downregulated, unchanged, and upregulated genes, respectively. The official gene symbol and RefSeq annotation number are shown
for each gene. MS = multiple sclerosis; TB = tuberculous meningitis; CO = control; Scale bars: A = 200 mm; B and C = 50 mm; D and
E = 100 mm.
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gene expression changes identified by our approach are related to
interconnected molecular pathways, which in part have been sug-
gested to operate in multiple sclerosis lesions before.
In conclusion, our study shows that focal plaque-like demyelin-
ation is a specific feature of cortical multiple sclerosis lesions and is
associated with excessive oxidative damage, mainly affecting
oligodendrocytes, neurons and their cell processes. The reason
for excessive oxidative injury remains currently unresolved and
may be related to the nature of the inflammatory process or to
factors determining the susceptibility of neuronal tissue to inflam-
mation in multiple sclerosis, such as brain ageing or accumulation
of pre-existing damage. To answer this question, more extensive
studies are necessary concentrating on highly active and inflam-
matory cortical multiple sclerosis lesions, which are very rare in
archival autopsy material, but are sometimes seen in biopsies of
multiple sclerosis brain tissue obtained during the early stages of
the disease (Lucchinetti et al., 2011).
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